AI-powered search
AI-powered search

2024 Virtual Grand Rounds

2024 Virtual Grand Rounds Session 12: September 25, 2024 - New Targets in Atopic Dermatitis: What’s on Deck?

About

Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:

Wednesday, September 25, 2024

8 PM ET / 5 PM PT

New Targets in Atopic Dermatitis: What's on Deck?

This activity is supported by educational grants from Arcutis Biotherapeutics, Inc., Dermavant Sciences, Inc., Galderma, and Lilly USA, LLC.

Availability

In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

September 26, 2024

Expiration Date:

September 26, 2025

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Describe the novel mechanisms of action of targeted atopic dermatitis (AD) therapies

  • Review the efficacy and safety from key clinical trials in emerging therapies for atopic dermatitis (AD)

Intended Audience

This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.

Faculty
Tiffany
Tiffany Mayo, MD

Associate Professor

The University of Alabama at Birmingham

Dermatology Vice Chair of Diversity, Equity and Inclusion

Department Director of Clinical Trials

Birmingham, Alabama

 

Marc
Marc Serota, MD

CEO, MD Integrations
Faculty, University of Colorado
Denver, CO

Lisa
Lisa Swanson, MD

Pediatric Dermatologist 
Ada West Dermatology 
Boise, ID

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

Disclosures are as follows:

Tiffany Mayo, MD

Advisory Board: Abbvie, Arcutis, BMS, Bodewell, Janssen, Lilly, Leo Novartis, Pfizer, UCB

Grant/Research Support: Acelyrin, BMS, ChemoCentryx, Galderma, Janssen, Lilly, Pfizer

Marc Serota, MD

Speakers Bureau: Arcutis, Amgen, BMS, Dermavant, Incyte, Sanofi Regeneron, Pfizer, Lilly, UCB

Lisa A. Swanson, MD

Consultant: Janssen, Lilly, Ortho Dermatologics, Sanofi-Regeneron, Pfizer, LEO, Novan, Arcutis

Speakers’ Bureau or Honoraria: Ortho Dermatologics, Pfizer, Amgen, Sanofi-Regeneron, Almirall, Janssen, Lilly, Novartis, Abbvie, Incyte 

The Institute discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved